Literature DB >> 17889365

Towards a dengue vaccine: progress to date and remaining challenges.

Bruno Guy1, Jeffrey W Almond.   

Abstract

The increased incidence and extended geographical reach of Dengue virus over the past two decades have made the development of an effective vaccine an international urgency. Various strategies are being pursued, including live, vectored and killed/recombinant preparations. For all approaches, the challenge is to induce a broad durable immune response against all four serotypes of Dengue virus simultaneously whilst avoiding the possible exacerbation of risk of developing the severe forms of disease through incomplete or modified responses. This review presents the current state of knowledge and discusses the challenges of further clinical development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17889365     DOI: 10.1016/j.cimid.2007.07.011

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  12 in total

1.  Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.

Authors:  Anke Harenberg; Sarah Begue; Audrey Mamessier; Sophie Gimenez-Fourage; Ching Ching Seah; Ai Wei Liang; Jun Li Ng; Xue Yun Toh; Sophia Archuleta; Annelies Wilder-Smith; Lynette P Shek; Anh Wartel-Tram; Alain Bouckenooghe; Jean Lang; Denis Crevat; Catherine Caillet; Bruno Guy
Journal:  Hum Vaccin Immunother       Date:  2013-07-09       Impact factor: 3.452

2.  Epidemics with multistrain interactions: the interplay between cross immunity and antibody-dependent enhancement.

Authors:  Simone Bianco; Leah B Shaw; Ira B Schwartz
Journal:  Chaos       Date:  2009-12       Impact factor: 3.642

3.  Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.

Authors:  David A Stein; Stuart T Perry; Michael D Buck; Christopher S Oehmen; Matthew A Fischer; Elizabeth Poore; Jessica L Smith; Alissa M Lancaster; Alec J Hirsch; Mark K Slifka; Jay A Nelson; Sujan Shresta; Klaus Früh
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

4.  Flavitrack analysis of the structure and function of West Nile non-structural proteins.

Authors:  Petr Danecek; Catherine H Schein
Journal:  Int J Bioinform Res Appl       Date:  2010

Review 5.  Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease.

Authors:  Scott C Weaver; Nikos Vasilakis
Journal:  Infect Genet Evol       Date:  2009-02-13       Impact factor: 3.342

6.  Aedes aegypti SNAP and a calcium transporter ATPase influence dengue virus dissemination.

Authors:  Alejandro Marin-Lopez; Junjun Jiang; Yuchen Wang; Yongguo Cao; Tyler MacNeil; Andrew K Hastings; Erol Fikrig
Journal:  PLoS Negl Trop Dis       Date:  2021-06-11

7.  Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2.

Authors:  Junu A George; Seong Kug Eo
Journal:  Immune Netw       Date:  2011-10-31       Impact factor: 6.303

8.  Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus.

Authors:  Shih-shiung Huang; I-Hsun Li; Po-da Hong; Ming-kung Yeh
Journal:  Int J Nanomedicine       Date:  2013-08-19

9.  Nuclear localization of dengue virus nonstructural protein 5 does not strictly correlate with efficient viral RNA replication and inhibition of type I interferon signaling.

Authors:  Anil Kumar; Sandra Bühler; Barbara Selisko; Andrew Davidson; Klaas Mulder; Bruno Canard; Sven Miller; Ralf Bartenschlager
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

10.  Dengue virus type 3 adaptive changes during epidemics in São Jose de Rio Preto, Brazil, 2006-2007.

Authors:  Christian Julian Villabona-Arenas; Adriano Mondini; Irene Bosch; Diane J Schimdt; Diane Schimitt; Carlos E Calzavara-Silva; Paolo M de A Zanotto; Maurício L Nogueira
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.